Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

DMAC
DiaMedica Therapeutics Inc. Common Stock
stock NASDAQ

At Close
Aug 6, 2026 3:59:47 PM EDT
6.77USD+1.575%(+0.11)76,664
0.00Bid   0.00Ask   0.00Spread
Pre-market
0.00USD-100.000%(-6.67)0
After-hours
Aug 6, 2026 4:47:30 PM EDT
6.77USD0.000%(0.00)432
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
08:43AM EST  DiaMedica Therapeutics to Present Research at International Stroke Conference   Business Wire
Jan 5, 2022
08:52AM EST  DiaMedica Therapeutics Appoints Kirsten Gruis As Chief Medical Officer   RTTNews
08:42AM EST  DiaMedica Therapeutics Appoints Dr. Kirsten Gruis As Chief Medical Officer   Benzinga
Dec 13, 2021
08:23AM EST  DiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access Event   Business Wire
Nov 17, 2021
08:23AM EST  DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference   Business Wire
Nov 10, 2021
06:43PM EST  DiaMedica Therapeutics Q3 EPS $(0.18) Beats $(0.23) Estimate   Benzinga
04:35PM EST  DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial Results   Business Wire
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Nov 9, 2021
04:07PM EST  DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021   Business Wire
Nov 8, 2021
08:36AM EST  DiaMedica Therapeutics Announces Addition Of Stroke Recurrence As A Second Independent Primary Endpoint In ReMEDy2 Phase 2/3 AIS Trial   Benzinga
Nov 4, 2021
08:30AM EDT  DiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021   Business Wire
08:19AM EDT  The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO   Benzinga
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 18, 2021
08:51AM EDT  DiaMedica Therapeutics Highlights Late-Breaking Data From Phase 2 REDUX Trial Of Its Chronic Kidney Disease Candidate At American Society Of Nephrology Kidney Meeting Nov. 4 At 1 p.m. EDT   Benzinga
08:39AM EDT  DiaMedica Announces Late Breaking Data From REDUX Phase 2 Trial To Be Presented At ASN Kidney Week 2021   RTTNews
08:30AM EDT  DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021   Business Wire
Oct 8, 2021
04:24PM EDT  DiaMedica Therapeutics 13G Filing From Trill Shows 9.6% New Stake In Co.   Benzinga
Oct 6, 2021
04:26PM EDT  DiaMedica Therapeutics 13G From Laurence Lytton Shows 5.2% Stake In Co.   Benzinga
Oct 5, 2021
05:05PM EDT  DiaMedica Therapeutics Files For Offering Of Up To 7.65M Common Shares   Benzinga
Sep 30, 2021
08:51AM EDT  DiaMedica Announces Fast Track Designation Granted To DM199 For Treatment Of Acute Ischemic Stroke   RTTNews
08:46AM EDT  DiaMedica Therapeutics Announces Fast Track Designation Granted To DM199 For Treatment Of Acute Ischemic Stroke   Benzinga
Sep 28, 2021
08:45AM EDT  DiaMedica Therapeutics Announces Closing of $30 Million Private Placement   Business Wire
Sep 27, 2021
12:34PM EDT  Mid-Day Market Update: Crude Oil Rises 2%; ASLAN Pharmaceuticals Shares Slide   Benzinga
08:47AM EDT  DiaMedica Announces $30 Mln Private Placement   RTTNews
08:46AM EDT  DiaMedica Therapeutics Announces $30M Private Placement At $3.92/Share   Benzinga
08:45AM EDT  DiaMedica Therapeutics Announces $30 Million Private Placement   Business Wire
Sep 13, 2021
09:10AM EDT  DiaMedica Therapeutics Inc. (DMAC) announced the initiation of the first site for its pivotal ReMEDy2 Trial, a Phase 2/3 clinical study of DM199 for the treatment of acute ischemic stroke or AIS.   RTTNews
08:48AM EDT  DiaMedica Therapeutics Initiates Pivotal Trial Of DM199 For Treatment Of Acute Ischemic Stroke   Benzinga
08:37AM EDT  DiaMedica Initiates Pivotal Trial Of DM199 For Treatment Of Acute Ischemic Stroke; Stock Up   RTTNews
08:32AM EDT  DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke   Business Wire
Sep 7, 2021
04:30PM EDT  DiaMedica Therapeutics to Participate at Upcoming Investor Conferences   Business Wire
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 11, 2021
04:58PM EDT  DiaMedica Therapeutics Q2 EPS $(0.17) Beats $(0.21) Estimate   Benzinga
04:30PM EDT  DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results   Business Wire
09:06AM EDT  Earnings Scheduled For August 11, 2021   Benzinga
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
04:27AM EDT  Earnings Scheduled For August 11, 2021   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 5, 2021
08:12AM EDT  DiaMedica Therapeutics to Report Second Quarter 2021 Financial Results and Provide a Business Update August 12, 2021   Business Wire
Jul 28, 2021
04:28PM EDT  DiaMedica Therapeutics to Participate in the BTIG Virtual Biotechnology Conference   Business Wire
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jun 30, 2021
11:30AM EDT  UPDATE: Roth Capital On DiaMedica Therapeutics Price Target Trim: Firm Cites 'Unclear Baseline Values Of UACR Levels' With Relationship To DM199 Dosage; Lowers Technology Value Attributed To Kidney Disease Programs From $200M To $50M   Benzinga
09:59AM EDT  Roth Capital Maintains Buy on DiaMedica Therapeutics, Lowers Price Target to $32   Benzinga
Jun 29, 2021
03:01PM EDT  Mid-Afternoon Market Update: US Stocks Mostly Flat; DiaMedica Therapeutics Shares Plunge   Benzinga
12:18PM EDT  Mid-Day Market Update: Gold Drops Over 1%; Cerevel Therapeutics Shares Spike Higher   Benzinga
11:16AM EDT  Mid-Morning Market Update: Markets Mostly Higher; FactSet Research Reports Mixed Q3 Results   Benzinga
10:29AM EDT  DiaMedica Therapeutics Inc. (DMAC) shares are sliding more than 31 percent on Tuesday morning trade after the company reported mixed results for the Phase 2 trial of DM199 in patients with chronic kidney disease.   RTTNews
10:16AM EDT  Mid-Morning Market Update: Markets Mostly Higher; FactSet Research Reports Mixed Q3 Results   Benzinga
09:14AM EDT  DiaMedica Therapeutics Stock Slips On Mixed DM199 Data In Chronic Kidney Disease Patients   Benzinga
08:17AM EDT  The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout   Benzinga
07:29AM EDT  DiaMedica Therapeutics Announces Positive Interim Results From Phase 2 REDUX Study In CKD   RTTNews
07:00AM EDT  DiaMedica Therapeutics Announces Interim Results From Phase 2 REDUX Study In CKD; Says Results 'Affirm Biological Activity, Safety and Tolerability of DM199' And Indicate 'Statistically and Clinically Significant Reduction in UACR'   Benzinga
06:58AM EDT  DiaMedica Therapeutics Announces Positive Interim Results from Phase 2 REDUX Study in CKD   Business Wire
May 17, 2021
12:28PM EDT  DiaMedica Stock Gains On Green Signal To Start Pivotal DM199 Trial In Ischemic Stroke   Benzinga
09:11AM EDT  DiaMedica Says FDA Accepted IND Application To Begin Phase 2/3 Clinical Trial For DM199 For Acute Ischemic Stroke   RTTNews
08:56AM EDT  DiaMedica Therapeutics Announces FDA Clearance Of IND Application To Initiate Phase 2/3 Clinical Trial For DM199 For Acute Ischemic Stroke   Benzinga
May 5, 2021
05:14PM EDT  DiaMedica Therapeutics Q1 EPS $(0.19) Beats $(0.21) Estimate   Benzinga
04:28PM EDT  DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2021 Financial Results   Business Wire
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
04:16AM EDT  Earnings Scheduled For May 5, 2021   Benzinga
Apr 28, 2021
04:04PM EDT  DiaMedica Therapeutics to Report First Quarter 2021 Financials and Provide a Business Update May 6, 2021   Business Wire
Apr 22, 2021
08:16AM EDT  DiaMedica Therapeutics to Participate in the B. Riley Securities' Neuroscience Conference   Business Wire
Apr 9, 2021
12:14PM EDT  Oppenheimer Initiates Coverage On DiaMedica Therapeutics with Outperform Rating, Announces Price Target of $27   Benzinga
Apr 5, 2021
08:14AM EDT  DiaMedica Therapeutics to Present Research at the National Kidney Foundation's 2021 Spring Clinical Meetings   Business Wire
Mar 10, 2021
04:38PM EST  DiaMedica Therapeutics S-3 Filing Shows Registration For $100M Mixed Securities Shelf Offering   Benzinga
04:05PM EST  DiaMedica Therapeutics FY20 EPS $(0.78), Up From $(0.89) YoY   Benzinga
04:04PM EST  DiaMedica Therapeutics Announces 2020 Financial Results and Provides a Business Update   Business Wire
08:52AM EST  DiaMedica Therapeutics to Present Research at International Stroke Virtual Conference   Business Wire
07:26AM EST  The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link   Benzinga
04:04AM EST  Earnings Scheduled For March 10, 2021   Benzinga
Mar 9, 2021
04:04PM EST  DiaMedica Therapeutics Hosting Key Opinion Leader Webinar on DM199 for Treatment of Acute Ischemic Stroke   Business Wire
Mar 8, 2021
05:44PM EST  DiaMedica Therapeutics to Participate at Upcoming Investor Conferences   Business Wire
Mar 6, 2021
10:58AM EST  The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings   Benzinga
Mar 3, 2021
04:04PM EST  DiaMedica Therapeutics to Report Fourth Quarter 2020 Financials and Provide a Business Update March 11, 2021   Business Wire
Feb 25, 2021
08:48AM EST  DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting   Business Wire
Feb 17, 2021
10:12AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2021   Benzinga
07:46AM EST  Roth Capital Initiates Coverage On DiaMedica Therapeutics with Buy Rating, Announces Price Target of $38   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 11, 2021
08:01AM EST  DiaMedica Therapeutics to Present at the H.C. Wainwright BioConnect Conference   Business Wire
Jan 5, 2021
08:39AM EST  The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data   Benzinga
Dec 15, 2020
08:15AM EST  DiaMedica Therapeutics Says Enrolled Last Patient In Diabetic Kidney Disease Cohort Of Phase 2 REDUX CKD Study   RTTNews
08:10AM EST  DiaMedica Therapeutics Announces Enrollment Of Last Patient In Diabetic Kidney Disease Cohort Of Phase 2 REDUX CKD Study   Benzinga
Dec 10, 2020
08:54AM EST  DiaMedica Recently Receives Written Responses From FDA Following Type B Pre-IND Meeting Request   RTTNews
08:07AM EST  DiaMedica Therapeutics Announces Successful Type B Meeting With FDA For Study Of DM199 In Patients With Acute Ischemic Stroke; Co. Plans To Submit IND Application For Phase 2/3 Study In Q1 Of 2021   Benzinga
08:03AM EST  DiaMedica Therapeutics Announces Successful Type B Meeting with FDA for the Study of DM199 in Patients with Acute Ischemic Stroke   Business Wire
Nov 19, 2020
09:04AM EST  DiaMedica Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference   Business Wire
Nov 11, 2020
08:30AM EST  DiaMedica Therapeutics to Participate in 11th Annual Craig-Hallum Alpha Select Conference   Business Wire
Nov 10, 2020
11:28AM EST  Insider Buys DiaMedica Therapeutics Stock   Benzinga
Nov 4, 2020
05:03PM EST  DiaMedica Therapeutics Q3 EPS $(0.19) Up From $(0.20) YoY   Benzinga
04:30PM EST  DiaMedica Provides a Business Update and Third Quarter 2020 Financial Results   Business Wire
08:21AM EST  The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings   Benzinga
04:41AM EST  Earnings Scheduled For November 4, 2020   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 28, 2020
08:30AM EDT  DiaMedica Therapeutics to Report Third Quarter 2020 Financial Results and Provide a Business Update November 5, 2020   Business Wire
Sep 15, 2020
08:15AM EDT  DiaMedica Therapeutics to Present at Lake Street's Virtual 4th Annual (BIG4) Conference September 17, 2020   Business Wire
Sep 14, 2020
09:15AM EDT  DiaMedica Reports First Patients Dosed In Diabetic Kidney Disease Cohort In Phase 2 REDUX CKD Study   Benzinga
09:15AM EDT  DiaMedica Announces First Patients Dosed in Diabetic Kidney Disease Cohort in Phase II REDUX CKD Clinical Study   Business Wire
Aug 11, 2020
04:20PM EDT  DiaMedica Therapeutics Q2 EPS $(0.17) Up From $(0.21) YoY   Benzinga
04:05PM EDT  DiaMedica Provides a Business Update and Second Quarter 2020 Financial Results   Business Wire
04:02AM EDT  Earnings Scheduled For August 11, 2020   Benzinga
Aug 10, 2020
04:05PM EDT  DiaMedica Announces Closing of $23 Million Public Offering of Common Shares   Business Wire
Aug 6, 2020
04:05PM EDT  DiaMedica Therapeutics to Report Second Quarter 2020 Financials and Provide a Business Update August 12, 2020   Business Wire
09:23AM EDT  DiaMedica Announces The Pricing Of Its 4M Share Common Stock Offering At $5 Per Share   Benzinga
09:14AM EDT  DiaMedica Reports Pricing Of $20 Mln Public Offering Of Common Shares   RTTNews
09:05AM EDT  DiaMedica Announces Pricing of $20 Million Public Offering of Common Shares   Business Wire
07:57AM EDT  The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO   Benzinga
Aug 5, 2020
04:17PM EDT  DiaMedica Reports Offering Of Common Stock, No Size Disclosed   Benzinga
04:09PM EDT  DiaMedica Announces Proposed Public Offering of Common Shares; No Terms Disclosed   Benzinga
04:01PM EDT  DiaMedica Announces Proposed Public Offering of Common Shares   Business Wire
Jul 20, 2020
05:11AM EDT  80 Biggest Movers From Friday   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC